COVID-19 vaccine research could lead to drugs against HIV and cancer: Report

Vaccines against coronavirus were developed using a new techlogy which scientists are w using to create drugs against HIV, Cancer flu and similar ailments. All approved vaccine candidates were created using messenger RNA (mRNA), which does t use actual virus to create body’s immune response. success has inspired companies to accelerate efforts at using mRNA technique to tackle a host of or diseases, with Moderna anuncing three new vaccine projects earlier this month.

One of projects undertaken by Moderna includes a vaccine against HIV, which kills millions of people every year. company has alrey begun development of two vaccine candidates which are scheduled to undergo human trials later this year. Ar ambitious vaccine that American pharmaceutical is developing includes that against common flu.

Re: 'India A True Friend': US Lauds Move To Gift COVID-19 Vaccines To Several Countries

move has also inspired or companies to undertake similar projects. Speaking to NewsWeek, a representative of Pfizer revealed that company h been working on a common flu virus, along with BioNTech, since a very long time. Meanwhile, Moderna also anunced a project that aims at developing a vaccine against Nipah virus. In dendum, several or companies are aiming to develop vaccines against cancer using mRNA technique.  

Re: Vallance: Vaccines Appear To Be Effective Against UK Variant

How does new techlogy work? 

Tritional vaccines use modified or killed virus, or parts of protein present in virus, to train body's immune system to kill infections before y take hold. new mRNA vaccines prompt body to produce virus protein, which in case of COVID-19 is "spike" protein that coronavirus uses to infect cells, without using any of actual viruses, as reported by NewsWeek.

Re: COVID-19: Decision On UK's Universal Payment Scheme For Coronavirus Patients

Re: COVID-19: Hong Kong Places Residents Under 48-hour Lockdown, Initiated Testing

This comes as World Health Organization (WHO), on January 22, revealed that it h reached an agreement with Pfizer/BioNTech for 40 million doses of ir COVID-19 vaccine. deal was me as a part of UN ncy’s ambitious COVAX programme which aims at iculating residents in underdeveloped and developing countries. After successfully securing vaccines WHO w plans to begin ir roll out as early as February. Although a distribution plan has t been concreted as yet, experts have speculated that health workers would be prioritised.